<DOC>
	<DOCNO>NCT01298128</DOCNO>
	<brief_summary>The newly design contraceptive ring , Nuvaring low total steroid dose , medication deliver locally . It proven safe effective combine OCP ovarian suppression prevent ovulation few side effect due minimal systemic absorption . Following single vaginal insertion , steroid concentration remain stable 4 week . It hypothesize Nuvaring may , therefore lead good compliance , tolerability acceptance patient require ovarian suppression prior COH IVF .</brief_summary>
	<brief_title>NuvaRing v . Oral Contraceptive Pills ( OCP ) In-Vitro Fertilization ( IVF ) Pre-treatment</brief_title>
	<detailed_description />
	<mesh_term>Infertility</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<mesh_term>Contraceptives , Oral , Combined</mesh_term>
	<criteria>Patients le 38 year age . Healthy woman start first IVF/ICSI cycle . No contraindication Combined Oral Contraceptive ( COC ) use . Appendix 1 Consent randomization . Any contraindication COC use . Hypersensitivity Nuva ring component . Language barrier consent .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>38 Years</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>